Nabriva Therapeutics AG (NASDAQ:NBRV) had its target price raised by HC Wainwright from $18.00 to $20.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a hold rating to a buy rating and set a $9.25 price target on the stock in a research note on Wednesday, October 11th. Needham & Company LLC reiterated a buy rating and set a $18.00 price target (up previously from $15.00) on shares of Nabriva Therapeutics AG in a research note on Tuesday, September 19th. Wedbush reiterated an outperform rating and set a $21.00 price target (up previously from $13.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. Leerink Swann reiterated an outperform rating and set a $22.00 price target (up previously from $20.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. Finally, SunTrust Banks, Inc. lifted their price target on shares of Nabriva Therapeutics AG from $20.00 to $24.00 and gave the stock a buy rating in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. Nabriva Therapeutics AG has an average rating of Buy and an average target price of $19.03.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded up $0.39 during midday trading on Wednesday, reaching $6.14. 361,540 shares of the company were exchanged, compared to its average volume of 530,633. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. analysts anticipate that Nabriva Therapeutics AG will post -2.35 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Boosts Nabriva Therapeutics AG (NBRV) Price Target to $20.00” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/hc-wainwright-boosts-nabriva-therapeutics-ag-nbrv-price-target-to-20-00/1678434.html.

In other news, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were purchased at an average cost of $9.46 per share, for a total transaction of $497,889.26. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $10.50, for a total transaction of $186,795.00. Following the sale, the insider now owns 2,373,387 shares in the company, valued at $24,920,563.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 57,219 shares of company stock worth $535,919 and have sold 74,840 shares worth $714,161. 2.75% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Almanack Investment Partners LLC. raised its position in shares of Nabriva Therapeutics AG by 482.2% during the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after purchasing an additional 751,366 shares during the period. Nationwide Fund Advisors raised its position in shares of Nabriva Therapeutics AG by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares during the period. Finally, Royal Bank of Canada increased its holdings in Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 8,650 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.